CureGene announced that two abstracts on CG-1999, its lead investigational immunomodulator for functional cure of chronic Hepatitis B (CHB), have been officially selected as "Poster of Distinction" by the American Association for the Study of Liver Diseases (AASLD) for the 2025 AASLD Annual Meeting. Additionally, the related posters have been invited into the conference’s “Special Interest Groups” session on Hepatitis B, where they will be presented and discussed with leading experts in the field. The prestigious liver disease conference will take place in Washington, D.C., from November 7–11, 2025.

The two selected studies highlight the novel mechanism of action and preclinical data of CG-1999. This pipeline candidate uniquely activates specific immune pathways to modulate the host immune system, demonstrating great potential to suppress and eliminate chronic hepatitis B virus (HBV) infection. The AASLD "Poster of Distinction" designation is awarded only to the top 10% of abstracts based on scientific merit and innovation, signifying high recognition by a leading global academic institution of the scientific value and clinical potential of CureGene’s CG-1999 program.

“This is a significant milestone in the development of CG-1999,” said Dr. Xiao-Wu Chen, Project Lead at CureGene Pharmaceutical. “We remain deeply committed to advancing functional cure solutions for Hepatitis B. We look forward to sharing our breakthrough findings with the global scientific community at AASLD 2025 and accelerating the delivery of innovative therapies for nearly 300 million people living with chronic Hepatitis B worldwide.”

The two findings will be showcased in the poster session at AASLD 2025 on November 7, 2025, with abstract numbers #1130 and #1142. They will also be presented orally during the Hepatitis B Special Interest Groups session on the afternoon of November 9, 2025.

About CG-1999  
CG-1999 is a first-in-class immunomodulator developed in house by CureGene, designed to achieve functional cure of chronic Hepatitis B by restoring host immune responsiveness. The molecule specifically activates the innate and adaptive immune system to boost HBV-specific T-cell populations, enhance antigen presentation, and promote the development of durable immune memory. CG-1999 represents a promising therapeutic approach to overcome the limitations of current antiviral agents by directly addressing the problem of immune tolerance that underlies chronic HBV infection.

About AASLD  
The American Association for the Study of Liver Diseases (AASLD), founded in 1943, is the leading global scientific and medical organization dedicated to liver disease research and treatment. With over 16,000 members from more than 100 countries, AASLD’s annual liver meeting is the premier global event in hepatology and a key barometer of innovation in the field.

About CureGene 
CureGene was founded in 2018. Based in China, we strive to become a globally focused innovative biopharmaceutical company. We have established innovative platforms based on our core expertise and capability. Currently we are focused on cardio-cerebrovascular and antiviral disease areas. We have developed a number of pipelines of drugs with huge market potential and fully owned global IP rights and are actively moving these projects forward. Guided by our shared mission statement, we have assembled a group of talented and highly accomplished scientists with global pharmaceutical experience from China and overseas. With a comprehensive strategic vision, CureGene has successfully and highly efficiently moved from research stage startup into a clinical stage company, with all pipelines capable of First-in-Class or Best-in-Class potential.

Forward-Looking Statement
The information released in this press release may contain certain forward-looking statements (such as "will", "anticipate", "forecast", "expect", "intend", "plan", "believe", "estimate", "be confident" and other similar expressions), which are based on the current views, beliefs and expectations that the Company or its management has towards the Company’s business operations and financial performance when such statements are made. These forward-looking statements shall not be deemed as guarantees of future outcomes, and such outcomes may be affected by risks, uncertainties, and other factors, some of which are beyond the Company’s control and difficult to predict. Therefore, subject to the impacts of our business, general industry conditions and competition, environment, politics, general economic factors (including fluctuations in interest rates and exchange rates), pharmaceutical industry regulations and medical policies, technological developments, new products and patents obtained by any competitors, the inherent challenges in new product development (including obtaining regulatory approvals), production difficulties or delays, instability in the international economic and financial situation and sovereign risks, reliance on the effectiveness of the protection of the Company's patents and other innovative products, the Company's risks of facing patent litigation and/or regulatory actions, future changes and developments in social situations and other various factors and assumptions, the actual results may differ significantly from the information contained in the forward-looking statements.
Such forward-looking statements shall not in any way be considered as any commitments/guarantee made by the Company, its subsidiaries, or any of its directors, officers, management personnel, advisors, employees and/or agents regarding relevant matters. They do not constitute a recommendation to engage in a certain act. None of such personnel assumes any liability with respect to such forward-looking statements. Moreover, the Company and its subsidiaries, directors, management personnel, consultants, employees and/or agents have not and will not assume any responsibility for updating the forward-looking statements contained in this press release to reflect the latest information, future projects or circumstances or events that occur after the release date.